Jiang Leyu, Xiong Wei, Yang Yuqiao, Qian Jinqiao
Department of Anesthesiology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Cardiovasc Drugs Ther. 2024 Dec;38(6):1139-1159. doi: 10.1007/s10557-024-07579-9. Epub 2024 Jun 13.
Cardiovascular disease remains the leading cause of death worldwide. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist with sedative, analgesic, anxiolytic, and sympatholytic properties, and several studies have shown its possible protective effects in cardiac injury. The aim of this review is to further elucidate the underlying cardioprotective mechanisms of dexmedetomidine, thus suggesting its potential in the clinical management of cardiac injury.
Our review summarizes the findings related to the involvement of dexmedetomidine in cardiac injury and discusses the results in the light of different mechanisms. We found that numerous mechanisms may contribute to the cardioprotective effects of dexmedetomidine, including the regulation of programmed cell death, autophagy and fibrosis, alleviation of inflammatory response, endothelial dysfunction and microcirculatory derangements, improvement of mitochondrial dysregulation, hemodynamics, and arrhythmias. Dexmedetomidine may play a promising and beneficial role in the treatment of cardiovascular disease.
心血管疾病仍是全球首要死因。右美托咪定是一种高选择性α2肾上腺素能受体激动剂，具有镇静、镇痛、抗焦虑和抗交感神经作用，多项研究已表明其在心脏损伤中可能具有保护作用。本综述的目的是进一步阐明右美托咪定潜在的心脏保护机制，从而提示其在心脏损伤临床管理中的潜力。
我们的综述总结了与右美托咪定参与心脏损伤相关的研究结果，并根据不同机制对结果进行了讨论。我们发现，多种机制可能促成右美托咪定的心脏保护作用，包括对程序性细胞死亡、自噬和纤维化的调节，减轻炎症反应、内皮功能障碍和微循环紊乱，改善线粒体功能失调、血流动力学和心律失常。右美托咪定在心血管疾病治疗中可能发挥有前景且有益的作用。
